R
Rodney Dawson
Researcher at University of Cape Town
Publications - 87
Citations - 5012
Rodney Dawson is an academic researcher from University of Cape Town. The author has contributed to research in topics: Tuberculosis & Rifampicin. The author has an hindex of 35, co-authored 79 publications receiving 4119 citations.
Papers
More filters
Journal ArticleDOI
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
Andreas H. Diacon,Rodney Dawson,Florian von Groote-Bidlingmaier,Gregory Symons,Amour Venter,Peter R. Donald,Christo van Niekerk,Daniel Everitt,Helen Winter,Piet J. Becker,Mendel Carl M,Melvin Spigelman +11 more
TL;DR: PA-824-moxifloxacin-pyrazinamide is potentially suitable for treating drug-sensitive and multidrug-resistant tuberculosis and can contribute to reducing the time needed to develop new antituberculosis regimens.
Journal ArticleDOI
Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting
Grant Theron,Jonny Peter,Richard N. van Zyl-Smit,Hridesh Mishra,Elizabeth M. Streicher,Samuel Murray,Rodney Dawson,Andrew Whitelaw,Michael Hoelscher,Surendra K. Sharma,Madhukar Pai,Robin M. Warren,Keertan Dheda +12 more
TL;DR: XpertMTB/RIF outperformed smear microscopy, established a diagnosis in a significant proportion of patients with smear-negative TB, detected many highly likely TB cases missed by culture, and accurately ruled out rifampicin-resistant TB.
Journal ArticleDOI
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J. Boeree,Norbert Heinrich,Rob E. Aarnoutse,Andreas H. Diacon,Rodney Dawson,Sunita Rehal,Gibson S. Kibiki,Gavin J. Churchyard,Gavin J. Churchyard,Ian Sanne,Nyanda E. Ntinginya,Lilian T. Minja,Robert D Hunt,Salome Charalambous,Madeleine Hanekom,Hadija H. Semvua,Stellah G. Mpagama,Christina Manyama,Bariki Mtafya,Klaus Reither,Klaus Reither,Robert S. Wallis,Amour Venter,Kim Narunsky,Anka Mekota,Sonja Henne,Angela Colbers,Georgette Plemper van Balen,Stephen H. Gillespie,Patrick P. J. Phillips,Michael Hoelscher +30 more
TL;DR: A dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion in liquid media, and could be a promising component of future, shorter regimens for the treatment of tuberculosis.
Journal ArticleDOI
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Martin J. Boeree,Andreas H. Diacon,Rodney Dawson,Kim Narunsky,J. du Bois,Amour Venter,Patrick P. J. Phillips,Stephen H. Gillespie,Timothy D. McHugh,Michael Hoelscher,Norbert Heinrich,Sunita Rehal,D. van Soolingen,J. van Ingen,C. Magis-Escurra Ibanez,David M. Burger,G. Plemper van Balen,Rob E. Aarnoutse +17 more
TL;DR: There was a nonlinear increase in exposure to rifampin without an apparent ceiling effect and a greater estimated fall in bacterial load in the higher dosing groups, and two weeks of rifampsin up to 35 mg/kg was safe and well tolerated.
Journal ArticleDOI
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
Rodney Dawson,Andreas H. Diacon,Daniel Everitt,Christo van Niekerk,Peter R. Donald,Divan Aristo Burger,Divan Aristo Burger,Robert Schall,Robert Schall,Melvin Spigelman,Almari Conradie,Kathleen D. Eisenach,Amour Venter,Prudence Ive,Liesl Page-Shipp,Ebrahim Variava,Klaus Reither,Klaus Reither,Nyanda E. Ntinginya,Alexander Pym,Florian von Groote-Bidlingmaier,Mendel Carl M +21 more
TL;DR: A novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant tuberculosis during the first 8 weeks of treatment was investigated, and the combination of moxifloxacin, pretomanid, and pyrazinamide, was safe, well tolerated, and showed superior bactericidal activity.